Skip to content
Menu

Wedbush Maintains Outperform on CG Oncology, Raises Price Target to $91

Benzinga Newsdesk 11 hours ago

Analyst RatingsNewsPrice Target

This page contains a summary, not the full article. Continue to benzinga.com to read the original report.

Wedbush analyst Robert Driscoll maintains CG Oncology (NASDAQ:CGON) with a Outperform and raises the price target from $84 to $91.

Wedbush analyst Robert Driscoll maintains CG Oncology (NASDAQ:CGON) with a Outperform and raises the price target from $84 to $91.

Read at benzinga.com